Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from PYC Therapeutics Limited ( (AU:PYC) ) is now available.
PYC Therapeutics Limited has issued an updated notification to the ASX correcting a typographical error in a previously lodged Appendix 3G relating to unquoted equity securities. The company clarified that the option strike price for the relevant securities is A$2.52 per option rather than A$2.25 as originally recorded on 6 January 2026, a change that ensures accurate disclosure of the terms of its equity instruments for investors and other stakeholders but does not represent a new capital raising or change in overall financing strategy.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is an Australia-based biotechnology company listed on the ASX, focused on developing therapeutic technologies and treatments, particularly in the field of precision genetic and RNA-based medicines.
Average Trading Volume: 450,195
Technical Sentiment Signal: Buy
Current Market Cap: A$979.9M
Learn more about PYC stock on TipRanks’ Stock Analysis page.